Loading...
Loading...
In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on AbbVie
ABBV from Equal-Weight to Overweight, and raised the price target from $36.00 to $49.00.
In the report, Risinger noted, “We see multiple call options in the underappreciated pipeline over the next 18-mon. 2015E EPS of $3.96 is 15% above cons. 3.8% div yield remains attractive vs. peers.Raised 2020E EPS by >50% from $2.96 to $4.61. Key drivers:1) Pipeline sales from $5.0B to $7.2B, 2) Humira 2020E sales from $8.6B to $9.8B due to smaller assumed hit from oral JAK and biosimilar competitors, 3) higher GM on Humira due to est. $1B reduction in royalties (via COGS) when patents expire in '17-‘18.”
AbbVie closed on Friday at $42.39.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in